Page 15 - Martin Shkreli Case Study

"After over a week of trying to secure Daraprim for an uninsured patient
requiring Daraprim at Massachusetts General Hospital, I need
immediate assistance with expediting this case. ... We have been
provided with inaccurate/misleading information by the dedicated
Daraprim Team. ... This is a critical matter, visible at the highest levels of
our Infectious Disease Department." - Doctor at Massachusetts General
Hospital, Oct. 8. (4)

So Turing went into crisis mode, trying out discount programs and
struggling with PR:

"I think we are acting a little like a deer in the headlights, and need to
take some action steps now. If a hospital like Mass General is having

issues we are in trouble." - Ed Painter, head of investor relations, Oct. 8.
(4)

22nd September 2015 Shkreli
announced he would reduce the
cost of Daraprim.

Shkreli said that for people without
insurance Daraprim will cost only
$1 a pill. For everyone else,
insurance (copayment), which he
argued was paid for by corporate
America’s profits, would cover the cost. A copayment or copay is a fixed
payment for a covered service, paid when an individual receives service.
In the United States, copayment is a payment defined in an insurance
policy and paid by an insured person each time a medical service is
accessed.

“We’ve agreed to lower the price of Daraprim to a point that is more
affordable and is able to allow the company to make a profit, but a very
small profit, and we think these changes will be welcome.”

An alternative scenario was provided by Bloomberg (7) when it was
commented that:

“When Turing bought Daraprim and sought to boost its annual revenue

from $5 million to more than $200 million, the use of patient-aid funds